GSK expands FDA approval for RSV vaccine Arexvy to younger adults at risk

GSK has achieved a significant regulatory advancement with the FDA's expanded approval of its RSV vaccine Arexvy for younger adults aged 18 to 49 at increased risk of RSV-related lower respiratory tract disease. This approval places GSK on equal footing with Pfizer and Moderna, who previously secured FDA endorsements for their RSV vaccines. The broader clearance comes at a time when Arexvy's sales growth has plateaued, offering potential to boost uptake in a competitive and difficult vaccine market.